TrialPloS one2025

A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury.

Pavel I Pilipenko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.